News

Phase II study of BW-40202, a small interfering RNA (siRNA) therapy targeting complement factor B (CFB), is planned to commence in January 2026. The therapy is also being

The funds will help YolTech in advancing its clinical programmes and global strategic execution. Established in 2021, YolTech Therapeutics is stated to be advancing next-generation in vivo gene-editing

The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod

The Boston-based company secured backing from existing investors and new investors, including Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare

AS, a rare neurological disorder often diagnosed in infancy, affects approximately one in 21,000 individuals worldwide and is caused by the loss of function of the maternal UBE3A

The gut microbiome is composed of microorganisms, including viruses, bacteria, and fungi, that naturally reside in the human gut. The companies will work together to investigate solutions aimed

VWD is the most prevalent inherited bleeding disorder in the US, affecting over three million individuals, with both men and women equally susceptible. Vonvendi is also approved for

This designation applies when olomorasib is used in combination with the anti-PD-1 therapy Keytruda (pembrolizumab) for the initial treatment of unresectable advanced or metastatic non-small cell lung cancer

This therapy is aimed at addressing vision loss in children with this disease, a rare paediatric neurodegenerative disorder for which there is currently no treatment available for its